Sama Adnan

Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model Data validate the VivoVec™ platform in a translationally relevant model and support its transition into human clinical testing, offering a potential paradigm shift in the field of CAR T-cell therapies Key Study Findings VivoVec particles (VVPs) incorporating CD80 and CD58 costimulation proteins exhibit enhanced capacity for in vivo CAR T-cell generation and produce CAR T-cells with increased antitumor functionality compared to those produced from VVPs displaying anti-CD3 scFvs alone. Combining the anti-CD3 scFv together with the ligand binding domains of CD80 and CD58 into a single multi-domain fusion (MDF) protein markedly augments the particles’ ability to bind, activate, and transduce T-cells. VVPs incorporating MDF compatible with NHP T-cell activation and costimulation potently generate anti-CD20 CAR T-cells in vivo, comprising up to 65% https://lnkd.in/eqsSTKjf

18

According to the latest analysis from BiopharmIQ by Amp, Pennsylvania holds the #3 position in CGT ecosystems for companies with under 50 employees. However, as these companies grow, I hope they choose to mature in Philadelphia. Recently, I've had numerous conversations about the region's shortage of leadership/ executive talent. It's intriguing considering that 80% of Big Pharma is located within 90 miles of the city. What the CGT sector needs is more experienced leadership, and Big Pharma could serve as an excellent source for it. For the latest updates on Life Science and Biotech news in the Philadelphia region, join The Informal Philadelphia Life Science Group below!

3

I want to remind everyone about the upcoming 2024 Philly Cell & Gene Therapy Conference. Don't miss the "Talk-To-An-Investor" session on June 15th from 2:40 PM to 4:45 PM at the Sheraton Valley Forge Hotel.   This is a fantastic opportunity to engage in 15-minute discussions with esteemed investors if you’re looking for RNA/ASO Tx angled funding.   💡My Session Highlights - June 15th: 1️⃣ Bioanalytical Strategies for In Vivo Quantification of Nucleic Acid Therapy 2️⃣ Delivery Challenges of Oligo Nucleotide Therapy 3️⃣ Model-Informed Drug Development for Nucleic Acid Therapy   At Rockland Immunochemicals, Inc., we're making significant advancements with our ModDetect™ panels. These panels are designed to facilitate the detection of specific chemical modifications independent of the sequence or location of the modification and can be used to evaluate a variety of RNA Tx modalities and nucleic acid structures. We’re collaborating with institutions to continue driving innovation in nucleic acid therapeutics. I would be happy to discuss opportunities with you and help connect you with the right people at the conference.   Looking forward to seeing you there!   #PhillyCGT #CellAndGeneTherapy #RNAtherapy #NucleicAcidTherapy #Biotech #Investors #RocklandImmunochemicals

33